Disease · MONDO_0004989

breast carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. breast carcinoma. Diseases, record MONDO_0004989. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004989

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: breast carcinoma; Open Targets
Open Targets ID: MONDO_0004989; Open Targets
Other names: carcinoma of breast, carcinoma of the breast, mammary carcinoma; Open Targets
Disease Ontology: DOID:3459; Disease Ontology
NCI Thesaurus: C4872; NCI Thesaurus
Highest stage of its drugs: Approval, for 29 of its 67 drugs, from ClinicalTrials.gov, DailyMed and FDA; Open Targets

Drugs67

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Approval	DailyMed	22	10	10	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Approval	DailyMed	20	9	9	Drugs and targets
TRASTUZUMAB	CHEMBL1201585	Antibody	Approval	ClinicalTrials.gov and DailyMed	10	9	9	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Approval	ClinicalTrials.gov and DailyMed	15	8	8	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Approval	DailyMed	11	7	7	Drugs and targets
ANASTROZOLE	CHEMBL1399	Small molecule	Approval	DailyMed	37	4	3	Drugs and targets
TUCATINIB	CHEMBL3989868	Small molecule	Approval	ClinicalTrials.gov	4	4	4	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Approval	DailyMed	24	3	3	Drugs and targets
EXEMESTANE	CHEMBL1200374	Small molecule	Approval	DailyMed	6	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets

1 to 10 of 67

See all 67 drugs

Targets110

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	8	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 110

See all 110 targets

Trials51

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02614794	A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer	Phase 2	612	2020-09-28	HER2 Positive Breast Cancer	CAPECITABINE, TRASTUZUMAB, TUCATINIB	Its record names the disease	ClinicalTrials.gov
NCT03975647	A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer	Phase 3	466	2024-07-30	HER2-positive Breast Cancer	TRASTUZUMAB EMTANSINE, TUCATINIB	Its record names the disease	ClinicalTrials.gov
NCT02454972	Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors	Phase 2	345	2021-11-22	Advanced Solid Tumors	LURBINECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT00463788	Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer	Phase 2	181	2012-10-10	Breast Neoplasm	CETUXIMAB, CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02040857	Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer	Phase 2	162	2020-12-23	Breast Cancer	PALBOCICLIB	Its record names the disease	ClinicalTrials.gov
NCT04721977	A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)	Phase 2	66	2024-08-09	Breast Cancer	CAPECITABINE, TRASTUZUMAB, TUCATINIB	Its record names the disease	ClinicalTrials.gov
NCT00820170	Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194	Phase 1/2	55	2019-08-13	Breast Cancer	DASATINIB, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02061085	Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment	Phase 2	53	2025-06-08	Breast Neoplasm, Metastasis	ERIBULIN	Its record names the disease	ClinicalTrials.gov
NCT00088413	PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer	Phase 1/2	51	2019-04-16	Adenocarcinoma, Colorectal Cancer, Ovarian Cancer, Breast Cancer	SARGRAMOSTIM	Its record names the disease	ClinicalTrials.gov
NCT01708161	A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors	Phase 1/2	47	2018-06-28	PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors	ALPELISIB, GANITUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 51

See all 51 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tuc+Cap+Tra vs Pbo+Cap+Tra: deaths from any cause	262 of 410	152 of 202	612	NCT02614794	Trial comparisons
Tuc+Cap+Tra vs Pbo+Cap+Tra: serious adverse events	124 of 404	62 of 197	601	NCT02614794	Trial comparisons
Tucatinib+ Ado-trastuzumab Emtansine vs Placebo+ Ado-trastuzumab Emtansine: Number of Participants With Treatment Emergent Adverse Events (AEs)	230 of 231	233 of 233	464	NCT03975647	Trial comparisons
Placebo+ Ado-trastuzumab Emtansine vs Tucatinib+ Ado-trastuzumab Emtansine: deaths from any cause	63 of 233	71 of 231	464	NCT03975647	Trial comparisons
Placebo+ Ado-trastuzumab Emtansine vs Tucatinib+ Ado-trastuzumab Emtansine: serious adverse events	52 of 233	70 of 231	464	NCT03975647	Trial comparisons
Cisplatin and Cetuximab vs Cisplatin: Safety- Number of Participants Experiencing Any Adverse Event (AE)	114 of 114	57 of 57	171	NCT00463788	Trial comparisons
Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: deaths from any cause	1 of 25	0 of 26	51	NCT00088413	Trial comparisons
Colorectal Cancer and Non-Colorectal Cancer Cohort vs Breast Cancer and Ovarian Cancer Cohort: Number of Participants With Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE) v3.0 and v4.0	25 of 25	26 of 26	51	NCT00088413	Trial comparisons
Colorectal Cancer vs Non-Colorectal Cancer Cohort vs Breast and Ovarian Cohorts: serious adverse events	25 of 25	26 of 26	51	NCT00088413	Trial comparisons
Dose Level 1 - Docetaxel 75 mg/m^2 vs Dose Level 2 - Docetaxel 60 mg/m^2: serious adverse events	2 of 2	7 of 29	31	NCT00086957	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials45

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31250880	RESULT	1	PubMed
28243955	RESULT	1	PubMed
22068656	RESULT	1	PubMed
20679610	RESULT	1	PubMed
19332727	RESULT	1	PubMed
18483372	RESULT	1	PubMed
16983592	RESULT	1	PubMed
16606972	RESULT	1	PubMed
16087945	RESULT	1	PubMed
15837984	RESULT	1	PubMed

1 to 10 of 45

See all 45 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004989

GET https://conductscience.org/api/diseases/v1/MONDO_0004989/drugs?page=2

API reference For AI assistants